Headlands Technologies LLC Invests $864,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,338 shares of the biotechnology company's stock, valued at approximately $864,000.

A number of other institutional investors have also recently bought and sold shares of ASND. Candriam S.C.A. grew its stake in shares of Ascendis Pharma A/S by 96.6% during the 2nd quarter. Candriam S.C.A. now owns 195,347 shares of the biotechnology company's stock valued at $26,640,000 after buying an additional 95,972 shares during the period. Rhumbline Advisers increased its stake in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after acquiring an additional 143 shares during the last quarter. Searle & CO. purchased a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth about $205,000. Legato Capital Management LLC lifted its stake in shares of Ascendis Pharma A/S by 167.6% in the 2nd quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company's stock valued at $590,000 after purchasing an additional 2,708 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock worth $833,000 after purchasing an additional 4,205 shares during the period.

Ascendis Pharma A/S Price Performance

ASND traded up $0.88 during trading on Thursday, hitting $113.81. The company had a trading volume of 2,273,779 shares, compared to its average volume of 411,775. The company has a market cap of $6.63 billion, a PE ratio of -11.84 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The business has a 50-day moving average of $132.78 and a 200-day moving average of $137.00.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wells Fargo & Company cut their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an "overweight" rating on the stock in a report on Wednesday, September 4th. Cantor Fitzgerald reduced their target price on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an "overweight" rating on the stock in a report on Wednesday, September 4th. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a report on Wednesday, September 4th. Evercore ISI raised Ascendis Pharma A/S to a "strong-buy" rating in a research report on Monday, August 26th. Finally, The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of "Moderate Buy" and a consensus target price of $187.08.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.